• Oxurion provides update on clinical pipeline progress

    Friday January 7th 2022

  • VIB research at the basis of experimental gene therapy against dementia

    Wednesday December 22nd 2021

  • UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

    Friday December 10th 2021

  • MRM Health announces first patient dosed with next generation live microbiome consortia therapeutic MH002 in Phase 1b/2a study in patients with Ulcerative Colitis

    Wednesday December 8th 2021

  • Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study

    Tuesday December 7th 2021

  • Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion

    Tuesday December 7th 2021

  • S-Biomedic announces topline results of a successful clinical study in acne

    Friday November 26th 2021

  • Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Tuesday November 23rd 2021

  • Your news here?

  • OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)

    Monday November 15th 2021

  • Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

    Wednesday October 13th 2021

  • Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer

    Wednesday October 6th 2021


Strategic Partners